DRG Debuts Oncology Trial Monitor

In the US, Decision Resources Group (DRG) has launched an Oncology Clinical Trial Monitor, offering biopharma companies insight into clinical trials, pipelines and opportunities within the oncology arena.

DRG, which is owned by Piramal Healthcare, provides web-enabled research and predictive analytics, proprietary databases and consulting services to the sector worldwide. The new Oncology Clinical Trial Monitor offers a visual dashboard to help users understand the current and emerging competitive environment. A series of filters enables users to customize information on a range of attributes, including pipelines, trial design, patient recruitment, treatment combinations, primary endpoints, biomarkers, product classes and companies - and to monitor these trends over time. Users can create visual heatmaps of activity, revealing areas of potential opportunities for investment.

Andrew Merron (pictured), Executive Director, Oncology, comments: 'DRG's oncology experts interpret what is the most important data from clinical trials, tailoring the parameters and the usefulness of the data, to reflect the specific needs of companies developing oncology treatments. Rather than using automated data pulls, the data is generated, harmonized and interpreted by DRG's oncology experts (so that it is accurate and relevant), built by skilled data architects (so that it works), and updated weekly (so that it's timely)'.

Web site: www.decisionresourcesgroup.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.